Cardiopulmonary Risk Benefits of Budesonide/Glycopyrrolate/Formoterol Fumarate Triple Therapy: A Number Needed to Treat Post Hoc Analysis of the ETHOS Trial

被引：0

作者：

Singh, D. ^{[1
]}

Marshall, J. ^{[2
]}

Martinez, F. J. ^{[3
]}

Hurst, J. R. ^{[4
]}

Han, M. K. ^{[5
]}

Gale, C. P. ^{[6
,7
]}

Fredriksson, M. ^{[8
]}

Kisielewicz, D. ^{[9
]}

Mushunje, A. ^{[2
]}

Movitz, C. ^{[8
]}

Ojili, N.

Parikh, H. ^{[10
]}

Arya, N. ^{[11
]}

Bowen, K. ^{[10
]}

Patel, M. ^{[2
]}

机构：

[1] Manchester Univ NHS Fdn Hosp Trust, Univ Manchester, Manchester, England

[2] AstraZeneca, Cambridge, England

[3] Univ Massachusetts Chan, Worcester, MA USA

[4] UCL, London, England

[5] Univ Michigan, Ann Arbor, MI USA

[6] Univ Leeds, Leeds Teaching Hosp NHS Trust, Leeds, England

[7] Leeds Teaching Hosp NHS Trust, Dept Cardiol, Leeds, England

[8] AstraZeneca, Gothenburg, Sweden

[9] AstraZeneca, Barcelona, Spain

[10] AstraZeneca, Gaithersburg, MD USA

[11] AstraZeneca, Durham, NC USA

来源：

关键词：

D O I：

10.1164/ajrccm.2025.211.Abstracts.A1016

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

引用

页数：1